0001735276-24-000020.txt : 20240229
0001735276-24-000020.hdr.sgml : 20240229
20240229161842
ACCESSION NUMBER: 0001735276-24-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tanguler Tolga
CENTRAL INDEX KEY: 0001849458
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 24703937
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-02-27
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001849458
Tanguler Tolga
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE
MA
02142
0
1
0
0
EVP, Chief Commercial Officer
0
Common Stock
2024-02-27
4
M
0
1667
0.0
A
5737
D
Common Stock
2024-02-28
4
S
0
216
154.54
D
5521
D
Common Stock
2024-02-28
4
S
0
170
155.45
D
5351
D
Common Stock
2024-02-28
4
S
0
100
156.38
D
5251
D
Common Stock
2024-02-28
4
S
0
14
157.3
D
5237
D
Common Stock
2024-02-28
4
S
0
1
158.09
D
5236
D
Restricted Stock Units
2024-02-27
4
M
0
1667
0.0
D
Common Stock
1667
3333
D
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.
By: Stephen Hall, Attorney-in-Fact For: Tolga Tanguler
2024-02-29